What Is the Price of NeoFipronis (GS-441524)
Feline Infectious Peritonitis (FIP) is a severe and often fatal disease affecting cats worldwide. Caused by a mutated feline coronavirus, FIP manifests through symptoms such as loss of appetite, lethargy, fever, abdominal or chest fluid accumulation, lymphadenopathy, granulomas, neurological damage, and uveitis. Traditional treatment options have been limited, but recent advances have introduced highly effective antiviral therapies like NeoFipronis (Pronidesivir), which contains the active ingredient GS-441524.
NeoFipronis has gained recognition as a groundbreaking medication for treating FIP. Approved in March 2026 by the Ministry of Agriculture and Forestry of Laos (MAF), it is the first oral antiviral drug officially registered for FIP management. Its approval marks a significant breakthrough in veterinary medicine, providing pet owners and veterinarians with a safe, non-invasive, and highly effective treatment option. NeoFipronis’s rapid absorption, quick onset of action, good tolerability, and minimal side effects set it apart from previous treatments.
The active component, GS-441524, is a nucleoside analogue that inhibits viral replication, leading to a significant reduction in viral load within the cat’s body. This targeted approach helps manage and often reverse the progression of FIP, especially when administered properly and consistently. Extensive research and clinical practice support its impressive efficacy, transforming the outlook for many affected cats.
The recommended dosage is based on the cat's weight—15 mg per kilogram of body weight daily. Typically, this equates to half a tablet per day; for neurological or ocular types of FIP, dosage may be increased to 30 mg/kg under veterinary guidance. It is advised to give NeoFipronis on an empty stomach—either one hour before feeding or two hours after—to optimize absorption. Treatment duration should be at least 12 weeks without interruption to ensure full viral suppression and recovery.
Monitoring during treatment is crucial. Pet owners should observe changes in appetite, body temperature, and behavior, while veterinarians should periodically assess blood parameters and organ functions such as liver and kidney health. Although NeoFipronis is marketed as an over-the-counter medication, it is highly recommended to administer it under the supervision of a veterinarian to guarantee safety and efficacy.
The safety profile of NeoFipronis is excellent, with few reported adverse effects. However, adherence to prescribed dosages and treatment durations remains vital. This medication is intended solely for feline use and should never be administered to humans. To ensure quality assurance, buyers are advised to purchase NeoFipronis only through the official website or authorized distributors.
Price details for NeoFipronis (GS-441524) vary based on factors such as country, supplier, and treatment course lengths. Generally, a box containing 30 tablets (each tablet suited for a 15 mg dosage) can range from approximately $200 to $400 USD. Some suppliers offer discounts for bulk orders or extended treatment packages, but prices should always be verified through official channels to prevent counterfeit products.
In summary, NeoFipronis (Pronidesivir), with its active ingredient GS-441524, represents a major advancement in feline health. Its proven efficacy against FIP, combined with a favorable safety profile and official regulatory approval, makes it a vital tool in combating this once-untreatable disease. Pet owners seeking detailed pricing and availability should consult reputable veterinary suppliers or official NeoFipronis distributors to ensure authentic, quality medication for their cats.
